- Seres Therapeutics Inc MCRB Stocks are up Thursday morning as the FDA approved serums and Nestle Health Science Vowst (Fecal Microbiota Spores, Live-brpk), an orally administered microbiota-based therapeutic to prevent the recurrence of C. difficile Infection (CDI) in adults after antibiotic treatment for recurrent CDI (rCDI).
- VOWST is not indicated for the treatment of CDI.
- Based on data from the US Centers for Disease Control and Prevention (CDC), the companies expect 156,000 episodes in the US by 2023.
- In a pivotal phase 3 study, Vowst, previously called SER-109, helped 88% of patients clear infection and reduce recurrence after eight weeks, compared with 60% of patients receiving placebo.
- In addition, six months after treatment, 79% of the VOWST group was recurrence-free compared to 53% in the placebo group.
- In July 2021, Seres and Nestlé Health Science agreed to commercialize Vowst in the year United States and Canada together.
- Seres will receive a US$125 million milestone payment from Nestlé Health Science related to FDA approval of Vowst.
- After the commercialization of Vowst, each company is entitled to an equal share in commercial profits and losses.
- Price promotion: MCRB shares are up 13.12% to $7.24 during the premarket session last check Thursday.
© 2023 Benzinga.de. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
